News

Sentynl Therapeutics, a US-based biopharmaceutical company and subsidiary of Zydus Lifesciences, and Mereo BioPharma Group have entered into an option and licence agreement covering the US commercial

SOLIZE PARTNERS Corporation and Dassault Systèmes Japan have entered into a Consulting and System Integration Partner Programme agreement to help manufacturers accelerate digital transformation, improve operational efficiency and support innovation.

Evotec has entered into a strategic research and development collaboration with Odyssey Therapeutics to discover new small molecule treatments for autoimmune and inflammatory diseases.

SystImmune has dosed the first patient in its global Phase 3 BrenDeLL-Lung01 trial, which is evaluating the investigational antibody-drug conjugate (ADC) BL-M14D1 in combination with atezolizumab as a first-line treatment for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Phylo has entered into a collaboration with Chugai Pharmaceutical to deploy Biomni Lab, its agentic AI platform for biomedical research, across Chugai’s drug discovery programmes.

Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL).

Capsa Healthcare has introduced RoboPharma, powered by Axona, an integrated automation and enterprise software platform designed to support centralised pharmacy operations, including

AbCellera has entered into a collaboration with Vertex Pharmaceuticals to discover, develop, manufacture and commercialise multispecific T-cell engagers (TCEs) for the treatment of autoimmune

DKSH Healthcare has expanded its strategic partnership with Novartis in South Korea by adding the hypertension medicines Diovan® and Exforge® to its prescription drug portfolio. Under the agreement

Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately US$2.2 billion.